[1] Iloeje UH, Yang HI, Su J, et al. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology, 2006, 130: 678-86. doi:  10.1053/j.gastro.2005.11.016
[2] Jiang W, Liu T, Dong H, et al. Relationship Between Serum DNA Replication, Clinic opathological Characteristics and Prognosis of Hepatitis B Virus-associated Glomerulonephritis with Severe Proteinuria by Lamivudine Plus Adefovir Dipivoxil Combination Therapy. Biomed Environ Sci, 2015, 28: 206-13. http://www.besjournal.com/Articles/Archive/2015/No3/201503/t20150323_112595.html
[3] Dusheiko G. Treatment of HBeAg positive chronic hepatitis B:interferon or nucleoside analogues. Liver Int, 2013, 33: 137-50. https://www.ncbi.nlm.nih.gov/pubmed/23286858
[4] Randall RE, Goodbourn S. Interferons and viruses:an interplay between induction, signalling, antiviral responses and virus countermeasures. J Gen Virol, 2008, 89: 1-47. doi:  10.1099/vir.0.83391-0
[5] Konerman MA, Lok AS. Interferon Treatment for Hepatitis B. Clin Liver Dis, 2016, 20: 645-65. doi:  10.1016/j.cld.2016.06.002
[6] Perrillo R. Benefits and risks of interferon therapy for hepatitis B. Hepatology, 2009, 49: S103-S11. doi:  10.1002/hep.v49.5s
[7] Tseng TC1: Kao JH, Chen DS. Peginterferon α in the treatment of chronic hepatitis B. Expert OpinBiolTher, 2014, 14: 995-1006. https://www.ncbi.nlm.nih.gov/pubmed/24738850
[8] Chuaypen N, Sriprapun M, Praianantathavorn K, et al. Kinetics of serum HBsAg and intrahepatic cccDNA during pegylated interferon therapy in patients with HBeAg-positive and HBeAg-negative chronic hepatitis B. J Med Virol, 2017, 89: 130-8. doi:  10.1002/jmv.v89.1
[9] Li MH, Xie Y, Zhang L, et al. Hepatitis B surface antigen clearance in inactive hepatitis B surface antigen carriers treated with peginterferon alfa-2a. World J Hepatol, 2016, 8: 637-43. doi:  10.4254/wjh.v8.i15.637
[10] Chan HL, Wong VW, Tse AM, et al. Serum hepatitis B surface antigen quantitation can reflect hepatitis B virus in the liver and predict treatment response. Clin Gastroenterol Hepatol, 2007, 5: 1462-8. doi:  10.1016/j.cgh.2007.09.005
[11] Chan HL, Wong VW, Wong GL, et al. A longitudinal study on the natural history of serum hepatitis B surface antigen changes in chronic hepatitis B. Hepatology, 2010, 52: 1232-41 doi:  10.1002/hep.23803
[12] Brunetto MR, Oliveri F, Colombatto P, et al. Hepatitis B surface antigen serum levels help to distinguish active from inactive hepatitis B virus genotype D carriers. Gastroenterology, 2010, 139: 483-90. doi:  10.1053/j.gastro.2010.04.052
[13] Manesis EK, Papatheodoridis GV, Hadziyannis E. Significance of serum HBsAg levels for the definition of the inactive hepatitis B carrier state. Hepatology, 2010, 52: 560A. doi:  10.1016/j.jhep.2010.01.013
[14] European Association For The Study Of The Liver. EASL clinical practice guidelines:Management of chronic hepatitis B virus infection. J Hepatol, 2012, 57: 167-85. doi:  10.1016/j.jhep.2012.02.010
[15] Moucari R, Korevaar A, Lada O, et al. High rates of HBsAg seroconversion in HBeAg-positive chronic hepatitis B patients responding to interferon:A long-term follow-up study. J Hepatol, 2009, 50: 1084-92. doi:  10.1016/j.jhep.2009.01.016
[16] Kittner JM, Sprinzl MF, Grambihler A, et al. Adding pegylated interferon to a current nucleos(t)ide therapy leads to HBsAgseroconversion in a subgroup of patients with chronic hepatitis B. J ClinVirol, 2012, 54: 93-5. https://www.ncbi.nlm.nih.gov/pubmed/22365367
[17] Sarri G, Westby M, Bermingham S, et al. Diagnosis and management of chronic hepatitis B in children, young people, and adults:summary of NICE guidance. BMJ, 2013, 346: f3893. doi:  10.1136/bmj.f3893
[18] Terrault NA, Bzowej NH, Chang KM, et al. AASLD guidelines for treatment of chronic hepatitis B. Hepatology, 2016, 63: 261-83. doi:  10.1002/hep.v63.1
[19] Sarin SK, Kumar M, Lau GK, et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B:a 2015 update. Hepatol Int, 2016, 10: 1-98. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4722087/
[20] Chinese Society of Hepatology and Chinese Society of Infectious Diseases, Chinese Medical Association. The guideline of prevention and treatment for chronic hepatitis B (2015 version). Chinese Journal of Liver Diseases (Electronic Version), 2015, 1-18. (In Chinese)
[21] Jiang SZ, Gao ZY, Li T, et al. T3098C and T53C mutations of HBV genotype C is associated with HBV infection progress. Biomed Environ Sci, 2009, 22: 511-7. doi:  10.1016/S0895-3988(10)60009-8
[22] BBuster EH, Hansen BE, Lau GK, et al. Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alfa. Gastroenterology, 2009, 137: 2002-9. doi:  10.1053/j.gastro.2009.08.061
[23] Piratvisuth T, Lau G, Chao YC, et al. Sustained response to peginterferon alfa-2a (40 kD) with or without lamivudine in Asian patients with HBeAg-positive and HBeAg-negative chronic hepatitis B. Hepatol Int, 2008, 2: 102-10. doi:  10.1007/s12072-007-9022-5
[24] National Clinical Guideline Centre (UK). Hepatitis B (Chronic):Diagnosis and Management of Chronic Hepatitis B in Children, Young People and Adults. National Institute for Health and Care Excellence:Clinical Guidelines. 2013: London:National Institute for Health and Care Excellence (UK).
[25] Chu CM, Liaw YF. Spontaneous relapse of hepatitis in inactive HBsAg carriers. Hepatol Int, 2007, 1: 311-5. doi:  10.1007/s12072-007-9002-9
[26] Hsu YS, Chien RN, Yeh CT, et al. Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B. Hepatology, 2002, 35: 1522-7. doi:  10.1053/jhep.2002.33638
[27] Chu CM, Hung SJ, Lin J, et al. Natural history of hepatitis B e antigen to antibody seroconversion in patients with normal serum aminotransferase levels. Am J Med, 2004, 116: 829-34. doi:  10.1016/j.amjmed.2003.12.040
[28] Fattovich G, Olivari N, Pasino M, et al. Long-term outcome of chronic hepatitis B in Caucasian patients:mortality after 25 years. Gut, 2008, 57: 84-90. https://www.ncbi.nlm.nih.gov/pubmed/17715267
[29] Yang HI, Lu SN, Liaw YF, et al. Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med, 2002, 347: 168-74. doi:  10.1056/NEJMoa013215
[30] Lau GK, Piratvisuth T, Luo KX, et al. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med, 2005, 352: 2682-95. doi:  10.1056/NEJMoa043470
[31] Sun J, Ma H, Xie Q, et al. Response-guided peginterferon therapy in patients with HBeAg-positive chronic hepatitis B:A randomized controlled study. J Hepatol, 2016, 65: 674-82. doi:  10.1016/j.jhep.2016.05.024
[32] Lampertico P, Viganò, M, Di Costanzo GG, et al. Randomised study comparing 48 and 96 weeks peginterferon alpha-2a therapy in genotype D HBeAg-negative chronic hepatitis B. Gut, 2013, 62: 290-8. doi:  10.1136/gutjnl-2011-301430
[33] Sonneveld MJ, Hansen BE, Piratvisuth T, et al. Response-guided peginterferon therapy in hepatitis B e antigen-positive chronic hepatitis B using serum hepatitis B surface antigen levels. Hepatology, 2013, 58: 872-80. doi:  10.1002/hep.v58.3
[34] Rijckborst V, Ferenci P, Akdogan M, et al. Long-term follow-up of hepatitis B e antigen-negative patients treated with peginterferon alpha-2a:progressive decrease in hepatitis B surface antigen in responders. Eur J Gastroenterol Hepatol, 2012, 24: 1012-9. doi:  10.1097/MEG.0b013e3283557e23
[35] Goulis I, Karatapanis S, Akriviadis E, et al. On-treatment prediction of sustained response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B patients. Liver Int, 2015, 35: 1540-8. doi:  10.1111/liv.2015.35.issue-5
[36] Boglione L, Cusato J, Cariti G, et al. Role of HBsAg decline in patients with chronic hepatitis B HBeAg-negative and E genotype treated with pegylated-interferon. Antiviral Res, 2016, 136: 32-6. doi:  10.1016/j.antiviral.2016.10.011
[37] Piratvisuth T, Marcellin P, Popescu M, et al. Hepatitis B surface antigen:association with sustained response to peginterferon alfa-2a in hepatitis B e antigen-positive patients. Hepatol Int, 2013, 7: 429-36. doi:  10.1007/s12072-011-9280-0
[38] Liaw YF, Jia JD, Chan HLY, et al. Shorter durations and lower doses of peginterferon alfa-2a are associated with inferior hepatitis B e antigen seroconversion rates in hepatitis B virus genotypes B or C. Hepatology, 2011, 54: 1591-9. doi:  10.1002/hep.24555
[39] Nguyen T, Thompson AJV, Bowden S, et al. Hepatitis B surface antigen levels during the natural history of chronic hepatitis B:a perspective on Asia. J Hepatol, 2010, 52: 508-13. doi:  10.1016/j.jhep.2010.01.007
[40] Lampertico P, ViganòM, Galeota Lanza A, et al. PegBeLiver study:HBsAg decline at week 24 of extended peginterferon alfa-2a (PEG-IFNα-2a) therapy is significantly associated with post-treatment response in HBeAg-negative genotype d patients. J of Hepatol, 2011, 54: S293. http://www.sciencedirect.com/science/article/pii/S0168827811607320
[41] Takkenberg RB, Jansen L, de Niet A, et al. Baseline hepatitis B surface antigen (HBsAg) as predictor of sustained HBsAg loss in chronic hepatitis B patients treated with pegylated interferon-α2a and adefovir. Antivir Ther, 2013, 18: 895-904. doi:  10.3851/IMP2580
[42] Gong-Ying Chen, Meng-Fei Zhu, Jie Wang, et al. Baseline HBsAg predicts response to pegylated. World J Gastroenterol, 2014, 20: 8195-200. doi:  10.3748/wjg.v20.i25.8195